BOSTON (TheStreet) -- French investors holding shares of Genfit (GNFTF) are having trouble coping with the failure of the company's fatty liver disease drug GFT505. I know this because many of them (it feels like all of them!) have reached out to me via Twitter (TWTR) in the past few days to express their outrage over my bearish analysis of last Friday's GFT505 study results in NASH.
This is the first time I've been Twitter trolled in French. I like it. Much classier.